Linsidomine: Difference between revisions

	WikiDoc Resources for Linsidomine
Articles
Most recent articles on Linsidomine Most cited articles on Linsidomine Review articles on Linsidomine Articles on Linsidomine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Linsidomine Images of Linsidomine Photos of Linsidomine Podcasts & MP3s on Linsidomine Videos on Linsidomine
Evidence Based Medicine
Cochrane Collaboration on Linsidomine Bandolier on Linsidomine TRIP on Linsidomine
Clinical Trials
Ongoing Trials on Linsidomine at Clinical Trials.gov Trial results on Linsidomine Clinical Trials on Linsidomine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Linsidomine NICE Guidance on Linsidomine NHS PRODIGY Guidance FDA on Linsidomine CDC on Linsidomine
Books
Books on Linsidomine
News
Linsidomine in the news Be alerted to news on Linsidomine News trends on Linsidomine
Commentary
Blogs on Linsidomine
Definitions
Definitions of Linsidomine
Patient Resources / Community
Patient resources on Linsidomine Discussion groups on Linsidomine Patient Handouts on Linsidomine Directions to Hospitals Treating Linsidomine Risk calculators and risk factors for Linsidomine
Healthcare Provider Resources
Symptoms of Linsidomine Causes & Risk Factors for Linsidomine Diagnostic studies for Linsidomine Treatment of Linsidomine
Continuing Medical Education (CME)
CME Programs on Linsidomine
International
Linsidomine en Espanol Linsidomine en Francais
Business
Linsidomine in the Marketplace Patents on Linsidomine
Experimental / Informatics
List of terms related to Linsidomine

Linsidomine
Clinical data
ATC code	C01DX18 (WHO) ;
Identifiers
	IUPAC name 3-Morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;
PubChem CID	5219;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C6H10N4O2
Molar mass	170.17 g/mol

VisualWikitext

Latest revision as of 16:36, 20 August 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Linsidomine (3-morpholinosydnonimine or SIN-1^[1]) is a vasodilator. It is a metabolite of the antianginal drug molsidomine and acts by releasing NO from the endothelial cells nonenzymatically. It also hyperpolarizes the cell membrane through influencing the sodium-potassium pump and thereby rendering it less responsive to adrenergic stimulation. Linsidomine injection at a dose of 1 mg produces usable erection in about 70% of patients and full erection in up to 50% of patients. Linsidomine does not appear to be associated with priapism.

Linsidomine is neurotoxic and promotes oxidative stress on neurons.^[2] Linsidomine is a peroxynitrite-generating compound involved in the pathogenesis of neurodegenerative diseases.^[3]

References

↑ Wen, TC.; Rogido, MR.; Moore, JE.; Genetta, T.; Peng, H.; Sola, A. (Oct 2005). "Cardiotrophin-1 protects cortical neuronal cells against free radical-induced injuries in vitro". Neurosci Lett. 387 (1): 38–42. doi:10.1016/j.neulet.2005.07.018. PMID 16084018.
↑ Wallace, DR.; Dodson, S.; Nath, A.; Booze, RM. (Jan 2006). "Estrogen attenuates gp120- and tat1-72-induced oxidative stress and prevents loss of dopamine transporter function". Synapse. 59 (1): 51–60. doi:10.1002/syn.20214. PMID 16237680.
↑ Jang, JH.; Aruoma, OI.; Jen, LS.; Chung, HY.; Surh, YJ. (Feb 2004). "Ergothioneine rescues PC12 cells from beta-amyloid-induced apoptotic death". Free Radic Biol Med. 36 (3): 288–99. doi:10.1016/j.freeradbiomed.2003.11.005. PMID 15036348.

[Wen-2005-1] Wen, TC.; Rogido, MR.; Moore, JE.; Genetta, T.; Peng, H.; Sola, A. (Oct 2005). "Cardiotrophin-1 protects cortical neuronal cells against free radical-induced injuries in vitro". Neurosci Lett. 387 (1): 38–42. doi:10.1016/j.neulet.2005.07.018. PMID 16084018.

[Wallace-2006-2] Wallace, DR.; Dodson, S.; Nath, A.; Booze, RM. (Jan 2006). "Estrogen attenuates gp120- and tat1-72-induced oxidative stress and prevents loss of dopamine transporter function". Synapse. 59 (1): 51–60. doi:10.1002/syn.20214. PMID 16237680.

[Jang-2004-3] Jang, JH.; Aruoma, OI.; Jen, LS.; Chung, HY.; Surh, YJ. (Feb 2004). "Ergothioneine rescues PC12 cells from beta-amyloid-induced apoptotic death". Free Radic Biol Med. 36 (3): 288–99. doi:10.1016/j.freeradbiomed.2003.11.005. PMID 15036348.

[1]

[2]

[3]

@@ Line 25: / Line 25: @@
 | routes_of_administration =
 }}
+__NOTOC__
+{{SI}}
+{{CMG}}
-'''Linsidomine''' is a [[vasodilator]].
+==Overview==
+'''Linsidomine''' ('''3-morpholinosydnonimine''' or '''SIN-1'''<ref name="Wen-2005">{{Cite journal  | last1 = Wen | first1 = TC. | last2 = Rogido | first2 = MR. | last3 = Moore | first3 = JE. | last4 = Genetta | first4 = T. | last5 = Peng | first5 = H. | last6 = Sola | first6 = A. | title = Cardiotrophin-1 protects cortical neuronal cells against free radical-induced injuries in vitro. | journal = Neurosci Lett | volume = 387 | issue = 1 | pages = 38–42 |date=Oct 2005 | doi = 10.1016/j.neulet.2005.07.018 | PMID = 16084018 }}</ref>) is a [[vasodilator]]. It is a metabolite of the antianginal drug [[molsidomine]] and acts by releasing [[Nitric oxide|NO]] from the [[endothelial cell]]s nonenzymatically. It also hyperpolarizes the cell membrane through influencing the sodium-potassium pump and thereby rendering it less responsive to adrenergic stimulation. Linsidomine injection at a dose of 1&nbsp;mg produces usable erection in about 70% of patients and full erection in up to 50% of patients. Linsidomine does not appear to be associated with [[priapism]].
-{{CMG}}
+Linsidomine is neurotoxic and promotes [[oxidative stress]] on neurons.<ref name="Wallace-2006">{{Cite journal  | last1 = Wallace | first1 = DR. | last2 = Dodson | first2 = S. | last3 = Nath | first3 = A. | last4 = Booze | first4 = RM. | title = Estrogen attenuates gp120- and tat1-72-induced oxidative stress and prevents loss of dopamine transporter function. | journal = Synapse | volume = 59 | issue = 1 | pages = 51–60 |date=Jan 2006 | doi = 10.1002/syn.20214 | PMID = 16237680 }}</ref> Linsidomine is a [[peroxynitrite]]-generating compound involved in the pathogenesis of [[neurodegenerative diseases]].<ref name="Jang-2004">{{Cite journal  | last1 = Jang | first1 = JH. | last2 = Aruoma | first2 = OI. | last3 = Jen | first3 = LS. | last4 = Chung | first4 = HY. | last5 = Surh | first5 = YJ. | title = Ergothioneine rescues PC12 cells from beta-amyloid-induced apoptotic death. | journal = Free Radic Biol Med | volume = 36 | issue = 3 | pages = 288–99 |date=Feb 2004 | doi = 10.1016/j.freeradbiomed.2003.11.005 | PMID = 15036348 }}</ref>
+==References==
+{{reflist|2}}
 {{Vasodilators used in cardiac diseases}}
-[[Category:Morpholines]]
+[[Category:Cardiovascular Drugs]]
+[[Category:Drug]]
 [[Category:Vasodilators]]
-{{WH}}
-{{WS}}

v t e Vasodilators used in cardiac diseases (C01D)
Nitrates	Glyceryl trinitrate • Isosorbide dinitrate • Isosorbide mononitrate • Molsidomine • Pentaerythritol tetranitrate
Quinolone vasodilators	Flosequinan
Others	Itramin tosilate • Prenylamine • Oxyfedrine • Benziodarone • Carbocromen • Hexobendine • Etafenone • Heptaminol • Imolamine • Dilazep • Trapidil • Molsidomine • Efloxate • Cinepazet • Cloridarol • Nicorandil • Linsidomine • Nesiritide • Gapicomine

Clinical data

ATC code	C01DX18 (WHO)
Identifiers
IUPAC name 3-Morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine
PubChem CID	5219
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₆H₁₀N₄O₂
Molar mass	170.17 g/mol

Linsidomine: Difference between revisions

Latest revision as of 16:36, 20 August 2015

Overview

References

Navigation menu